DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0144300 A1 Magee Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0144300 A1 Magee Et Al US 2003O144300A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0144300 A1 Magee et al. (43) Pub. Date: Jul. 31, 2003 (54) PYRIMIDINE CARBOXAMIDES USEFUL AS Related U.S. Application Data INHIBITORS OF PDE4 ISOZYMES (60) Provisional application No. 60/179,282, filed on Jan. (76) Inventors: Thomas Victor Magee, Mystic, CT 31, 2000. (US); Anthony Marfat, Mystic, CT (US); Robert James Chambers, Publication Classification Mystic, CT (US) (51) Int. Cl." ...................... A61K 31/513; A61K 31/506 Correspondence Address: (52) U.S. Cl. ......................... 514/256; 514/269; 544/314; PFIZER INC. 544/326; 544/328 PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD (57) ABSTRACT GROTON, CT 06340 (US 9 (US) Compounds of formula (1.0.0) are described, as well as the (21) Appl. No.: 10/181,417 usefulness of a pharmaceutical composition for treating inflammatory, respiratory and allergic diseases and condi (22) PCT Filed: Jan. 30, 2001 tions, especially asthma, chronic obstructive pulmonary disease (COPD) including chronic bronchitis, emphysema, (86) PCT No.: PCT/IB01/00125 and bronchiectasis, chronic rhinitis, and chronic sinusitis. US 2003/O144300 A1 Jul. 31, 2003 PYRIMIDINE CARBOXAMIDES USEFULAS al., J. Med. Chem. 39 120-125, 1996; Schneider et al., INHIBITORS OF PDE4 ISOZYMES Pharmacol. Biochem. Behav: 50 211-217, 1995; Banner and Page, Br. J. Pharmacol. 11493-98, 1995; Barnette et al., J. 1.O REFERENCE TO COPENDING Pharmacol. Exp. Ther. 273 674-679, 1995; Wright et al. APPLICATIONS “Differential in vivo and in vitro bronchorelaxant activities 0001 Reference is made to copending International of CP-80633, a selective phosphodiesterase 4 inhibitor, application and US application based thereon, Serial No. "Can. J. Physiol. Pharmacol. 75 1001-1008, 1997; Manabe PCT/IB98/00315, both filed Mar. 10, 1998 (Attorney Docket et al. "Anti-inflammatory and bronchodilator properties of No. PC9762A), and published as WO 98/45268 on Oct. 15, KF19514, a phosphodiesterase 4 and 1 inhibitor, Eur: J. 1998; claiming priority from application Ser. No. 60/043, Pharmacol. 332 97-107, 1997; and Ukita et al. “Novel, 403 filed Apr. 4, 1997 (Attorney Docket No. PC9762), now potent, and Selective phosphodiesterase-4 inhibitors as anti abandoned; which discloses nicotinamide derivatives having asthmatic agents: Synthesis and biological activities of a biological activity as inhibitors of the PDE4 isozyme, and series of 1-pyridylnaphthalene derivatives.J. Med. Chem. thus useful in the treatment of inflammatory, respiratory and 42 1088-1099, 1999. Accordingly, there continues to be allergic diseases and conditions. Nothing that is disclosed in considerable interest in the art with regard to the discovery the above-mentioned applications would teach the perSon of of further Selective inhibitors of PDE4S. ordinary skill in the pertinent art the novel compounds of the 0006 The present invention is also concerned with the present invention or their unexpectedly high level of inhibi use of selective PDE4 inhibitors for the improved therapeu tory activity for the PDE4 isozyme. tic treatment of a number of inflammatory, respiratory and allergic diseases and conditions, but especially for the treat 0002 Reference is also made to copending application ment of asthma, chronic obstructive pulmonary disease Ser. No. 09/345,185 filed Jun. 30, 1999 (Attorney Docket (COPD) including chronic bronchitis, emphysema, and No. PC10096A); claiming priority from application Ser. No. bronchiectasis, chronic rhinitis, and chronic Sinusitis. Here 60/105,120 filed Oct. 21, 1998 (Attorney Docket No. tofore in the art, however, the first-line therapy for treatment PC10096), which discloses compounds and processes for of asthma and other obstructive airway diseases has been the preparing N-Substituted nicotinamide derivatives. However, nonselective PDE inhibitor theophylline, as well as pentoxi the disclosed compounds and processes are not the same as fylline and IBMX, which may be represented by Formulas those of the present invention. (0.0.1), (0,0.2), and (0.0.3), respectively: 0.003 Reference is further made to copending applica tions filed of even date with the instant application, Attorney Docket Nos. PC10523; PC10546; PC10657; PC10690; and (0.0.1) PC10691, which involve other classes of nicotinamide derivatives useful as selective inhibitors of the PDE4 isozyme. 2O BACKGROUND OF THE INVENTION 0004. The 3',5'-cyclic nucleotide phosphodiesterases ---CH (PDES) comprise a large class of enzymes divided into at least eleven different families which are structurally, bio Theophylline chemically and pharmacologically distinct from one another. (0.0.2) The enzymes within each family are commonly referred to O as isoenzymes, or isozymes. A total of more than fifteen gene N products is included within this class, and further diversity HC --~~ N r y H. results from differential Splicing and post-translational pro cessing of those gene products. The present invention is primarily concerned with the four gene products of the 1-2CH fourth family of PDEs, i.e., PDE4A, PDE4B, PDE4C, and PDE4D. These enzymes are collectively referred to as being Pentoxifylline isoforms or subtypes of the PDE4 isozyme family. Further (0.0.3) below will be found a more detailed discussion of the CH genomic organization, molecular structure and enzymatic activity, differential Splicing, transcriptional regulation and O l O phosphorylation, distribution and expression, and Selective CH N inhibition of the PDE4 isozyme subtypes. N 0005. The PDE4s are characterized by selective, high H3-N- C. affinity hydrolytic degradation of the Second messenger Ns/ cyclic nucleotide, adenosine 3',5'-cyclic monophosphate IBMX (cAMP), and by sensitivity to inhibition by rolipram. A number of selective inhibitors of the PDE4s have been discovered in recent years, and beneficial pharmacological 0007. Theophylline, which has the PDEs as one of its effects resulting from that inhibition have been shown in a biochemical targets, in addition to its well characterized variety of disease models. See, e.g., Torphy et al., Environ. bronchodilatory activity, affects the vasculature of patients Health Perspect 102 Suppl. 10, 79-84, 1994; Duplantier et with increased pulmonary artery pressure, Suppresses US 2003/O144300 A1 Jul. 31, 2003 inflammatory cell responses, and induces apoptosis of eosi 0009. However, benafentrine results in bronchodilation nophils. Theophylline's adverse events, most commonly only when administered by inhalation, and Zardaverine cardiac dysrhythmias and nausea, are also mediated by PDE produces only a modest and short-lived bronchodilation. inhibition, however, leading to the Search for more Selective Milrinone, a cardiotonic agent, induces short-lived bron inhibitors of PDEs that are able to suppress both immune chodilation and a slight degree of protection against induced cell functions in vitro and allergic pulmonary inflammation in Vivo, while at the same time having improved side-effect bronchoconstriction, but has marked adverse events, e.g., profiles. Within the airways of patients suffering from tachycardia and hypotension. Unsatisfactory results have asthma and other obstructive airway diseases, PDE4 is the also been obtained with a weakly selective PDE4 inhibitor, most important of the PDE isozymes as a target for drug tibenelast, and a selective PDE5 inhibitor, Zaprinast, which discovery because of its distribution in airway Smooth may be represented by Formulas (0.0.7) and (0,0.8): muscle and inflammatory cells. Several PDE4 inhibitors introduced to the art thus far have been designed to have an improved therapeutic indeX concerning the cardiovascular, (0.0.7) gastrointestinal, and central nervous System Side effects of the above-mentioned nonselective Xanthines. c C OH 0008 Airflow obstruction and airway inflammation are He1 No O features of asthma as well as COPD. While bronchial asthma Tibenelast is predominantly characterized by an eosinophilic inflam (0.0.8) mation, neutrophils appear to play a major role in the O pathogenesis of COPD. Thus, PDEs that are involved in H Smooth muscle relaxation and are also found in eosinophils N as well as neutrophils probably constitute an essential ele ment of the progress of both diseases. The PDEs involved \N / include PDE3s as well as PDE4s, and bronchodilating inhibitors have been discovered which are selective PDE3 O N-N inhibitors and dual PDE3/4 selective inhibitors. Examples of c1\1 H these are milrinone, a selective PDE3 inhibitor, as well as Zaprinast Zardaverine and benafentrine, both dual PDE3/4 selective inhibitors, which may be represented by Formulas (0.0.4), (0.0.5), and (0.0.6), respectively: 0010 More relative success has been obtained in the art with the discovery and development of selective PDE4 inhibitors. (0.0.4) 0011. In vivo, PDE4 inhibitors reduce the influx of eosi nophils to the lungs of allergen-challenged animals while also reducing the bronchoconstriction and elevated bron chial responsiveness occurring after allergen challenge. PDE4 inhibitors also suppress the activity of immune cells, Millrinone including CD4 T-lymphocytes, monocytes, mast cells, and (0.0.5) basophils; reduce pulmonary edema; inhibit excitatory FHC nonadrenergic noncholinergic neurotransmission (eNANC); potentiate inhibitory nonadrenergic noncholinergic neu O rotransmission (iNANC); reduce airway smooth muscle mitogenesis; and induce bronchodilation. PDE4 inhibitors N O a nY NH also SuppreSS the activity of a number of inflammatory cells
Load more

Recommended publications
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Piclamilast Item No. 29170 CAS Registry No.: 144035-83-6 Formal Name: 3-(cyclopentyloxy)-N-(3,5-dichloro- 4-pyridinyl)-4-methoxy-benzamide O Synonyms: RP 73401, RPR 73401 Cl H MF: C18H18Cl2N2O3 FW: 381.3 N O Purity: ≥98% O Supplied as: A solid N Storage: -20°C Cl Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Piclamilast is supplied as a solid. A stock solution may be made by dissolving the piclamilast in the solvent of choice, which should be purged with an inert gas. Piclamilast is soluble in organic solvents such as ethanol and DMSO. The solubility of piclamilast in ethanol is approximately 20 mM and approximately 100 mM in DMSO. Description 1 Piclamilast is a phosphodiesterase 4 (PDE4) inhibitor (IC50 = 0.31 nM). It is selective for PDE4 over PDE1, 2,3 PDE2, PDE3, PDE5, and PDE7A in cell-free assays (IC50s = >100, 40, >100, 14, and >10 μM, respectively). Piclamilast inhibits superoxide production by guinea pig eosinophils and histamine-induced contraction 1,4 in isolated guinea pig trachea (IC50s = 24 and 2 nM, respectively). It inhibits eosinophil, neutrophil, lymphocyte, and TNF-α accumulation in bronchoalveolar lavage fluid (BALF) from ovalbumin-sensitized 5 rats (ED50s = 23.8, 14.1, 19.5, and 14.4 μmol/kg, respectively). Piclamilast also inhibits ovalbumin-induced 2 bronchoconstriction in a guinea pig model of asthma (ED50 = 0.033 mg/kg). References 1. Ashton, M.J., Cook, D.C., Fenton, G., et al. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents.
    [Show full text]
  • [3H]-Piclamilast and [3H]-Rolipram
    JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 JPET FastThis articleForward. has not Published been copyedited on and January formatted. 24,The final2003 version as DOI:10.1124/jpet.102.047407 may differ from this version. Inhibitor Binding to Type 4 Phosphodiesterase (PDE4) Assessed Using [3H]-Piclamilast and [3H]-Rolipram Yu Zhao, Han-Ting Zhang, and James M. O’Donnell Department of Pharmacology University of Tennessee Health Science Center Downloaded from Memphis, Tennessee jpet.aspetjournals.org at ASPET Journals on September 27, 2021 1 Copyright 2003 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Inhibitor binding to PDE4 Correspondence should be addressed to: James M. O’Donnell, Ph.D. Department of Pharmacology University of Tennessee Health Science Center 874 Union Avenue Downloaded from Memphis, TN 38163 jpet.aspetjournals.org Phone: 901-448-3621 Fax: 901-448-3849 Email: [email protected] at ASPET Journals on September 27, 2021 Number of text page: 31 Number of tables: 3 Number of figures: 7 Number of references: 50 Number of words: Abstract (241); Introduction (716); Discussion (1544) Abbreviations: EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; HARBS, high-affinity rolipram binding site; LARBS, low-affinity rolipram binding site; IBMX, 3-isobutyl-1- methylxanthine; PDE, phosphodiesterase Section: Neuropharmacology 2 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted.
    [Show full text]
  • Chapter Introduction
    VU Research Portal Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis Jansen, C.J.W. 2015 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Jansen, C. J. W. (2015). Trypanosoma brucei phosphodiesterase B1 as a drug target for Human African Trypanosomiasis. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 05. Oct. 2021 An introduction into phosphodiesterases and their potential role as drug targets for neglected diseases Chapter 1 4 CHAPTER 1 1.1 Human African Trypanosomiasis Human African Trypanomiasis (HAT), also known as African sleeping sickness, is a deadly infectious disease caused by the kinetoplastid Trypanosoma
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • Inhibition of Phosphodiesterase 4 Modulates Cytokine Induction From
    University of Groningen Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle Van Ly, David; De Pedro, Monique; James, Peter; Morgan, Lucy; Black, Judith L.; Burgess, Janette K.; Oliver, Brian G. G. Published in: Respiratory Research DOI: 10.1186/1465-9921-14-127 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2013 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Van Ly, D., De Pedro, M., James, P., Morgan, L., Black, J. L., Burgess, J. K., & Oliver, B. G. G. (2013). Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle. Respiratory Research, 14, [127]. https://doi.org/10.1186/1465-9921-14-127 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE
    H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade H av on emeyer Foundati Havemeyer Foundation Monograph Series No. 9 Proceedings of a Workshop on INFLAMMATORY AIRWAY DISEASE: DEFINING THE SYNDROME 30th September – 3rd October 2002 Boston, USA Editors: A. Hoffman, N. E. Robinson and J. F. Wade © 2003 by R & W Publications (Newmarket) Limited Suites 3 & 4, 8 Kings Court, Willie Snaith Road, Newmarket, Suffolk CB8 7SG, UK No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. Authorisation to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by R & W Publications (Newmarket) Limited for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of £0.02 per copy (no additional fee per page) is paid directly to CCC, 21 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. First published 2003 ISSN 1472-3158 Published by R & W Publications (Newmarket) Limited Printed in Great Britain by Quality Print Services (Anglia) Limited Havemeyer Foundation Monograph Series No. 9 CONTENTS EDITORS’ FOREWORD .....................................................................................................................Page v SESSION 1: CLINICAL EVIDENCE Inflammatory airway disease: a clinician’s view from North America B.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Suplementum 12/1 MAKETA 7/1 2/23/12 12:12 PM Stránka 16
    suplementum 12/1 _MAKETA 7/1 2/23/12 12:12 PM Stránka 16 16 ACTA MEDICA MARTINIANA 2012 Suppl. 1 DOI: 10.2478/v10201-011-0023-7 SELECTIVE INHIBITION OF PHOSPHODIESTERASE 7 (PDE7) BY BRL50481 IN HEALTHY AND OVALBUMIN-SENSITIZED GUINEA PIGS Christensen I.1, Miskovicova H. 1, Porvaznik I.1,JoskovaM.1, Mokra D.2, Mokry J.1 1Department of Pharmacology Jessenius Faculty of Medicine, Comenius University, Martin 2Department of Physiology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic A b stract Phosphodiesterase (PDE) inhibitors may have significant clinical benefit in respiratory diseases associated with inflammation. The aim was to evaluate effects of selective PDE7 inhibitor (BRL50481) on citric acid induced cough, in vivo and in vitro airway smooth muscle reactivity in both healthy and ovalbumin sensitized guinea pigs, as well as its effectiveness in changes of blood cells count. Tested drugs were administered intraperitoneally to male guinea pigs once daily for 7 days either vehicle 10% DMSO (dimethyl sulfoxide) 3 ml/kg (as control) or BRL50481 1 mg/kg. Double chamber whole body plethysmo- graph was used for evaluation of citric acid (0.6 M) induced cough and specific airway resistance. Organ bath method was used for measurement of tracheal and lung tissue strips contractions evoked by cumulative doses (10- 8 – 10-3 mol/L) of acetylcholine (ACH) and histamine (HIS). In healthy guinea pigs we did not observe significant effect of tested drug BRL50481 on in vitro contractions (sim- ilarly to in vivo conditions). The effect on cough was in healthy animals negligible. In ovalbumin-sensitized ani- mals, more pronounced in vitro relaxing effect of BRL50481 in HIS induced contractions was observed with simi- lar results in vivo and no significant change in number of cough efforts.
    [Show full text]
  • New Therapeutic Options in the Management of COPD – Focus on Roflumilast
    International Journal of COPD Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW New therapeutic options in the management of COPD – focus on roflumilast Sabina Antonela Antoniu Abstract: In chronic obstructive pulmonary disease (COPD) the inflammation occurring in the University of Medicine and Pharmacy, airways and in other lung tissues is complex and is orchestrated by various mediators including the Pulmonary Disease Division, isoenzyme 4 of the phosphodiesterases family (PDE4), which contributes to bronchoconstriction Pulmonary Disease University and inflammation. Various PDE4 inhibitors have been evaluated as potential therapies in asthma Hospital, Iasi, Romania or COPD but among these only roflumilast have been authorized in Europe to be used in patients with severe COPD as an add-on to the bronchodilator therapy. This review discusses the existing preclinical and clinical data supporting the use of roflumilast for this therapeutic indication and tackles some of the pending issues related to PDE4 in general and to roflumilast in particular. Keywords: COPD, roflumilast, PDE4, efficacy, safety Introduction COPD is an inflammatory disease of the airways related mainly to smoking and char- acterized by airflow limitation, which manifests clinically with dsypnea, cough, and sputum production, symptoms that aggravate disease severity and disease exacerbation. Chronic airways inflammation leads to their progressive obstruction, lung paren- chyma damage, and mucus hypersecretion. Subsequently these result in abnormalities in gas exchange at the pulmonary level and respiratory failure. Currently COPD is classified in 4 stages of severity depending on the degree of airways obstruction measured by FEV1 and with FEV1/FVC% ratio (Table 1). In COPD the therapeutic approach is aimed at treating disease exacerbation when this occurs and at slowing disease progression in the stable state.
    [Show full text]
  • Downloaded from Survive Nursing | Survivenursing.Com V20110426
    Generic Stem Stem Definition Examples -abine (see -arabine, -citabine) decitabine -ac Anti-inflammatory agents (acetic acid derivatives) bromfenac; dexpemedolac -acetam See -racetam -actide Synthetic corticotropins seractide -adol or -aldol- Analgesics (mixed opiate receptor agonists/ antagonists) tazadolene; spiradolene; levonantradol -adox Antibacterials (quinoline dioxide derivatives) carbadox -afenone Antiarrhythmics (propafenone derivatives) alprafenone; diprafenone -afil PDE5 inhibitors tadalafil -aj- Antiarrhythmics (ajmaline derivatives) lorajmine -aldrate Antacid aluminum salts magaldrate -algron Alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol Combined alpha and beta blockers labetalol; medroxalol -amivir (see -vir) -ampa Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) -ampanel Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; becampanel antagonists -ampator Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; forampator modulators -andr- Androgens nandrolone -anib Angiogenesis inhibitors semaxanib -anserin Serotonin 5-HT2 receptor antagonists altanserin; tropanserin; adatanserin -antel Anthelmintics (undefined group) carbantel -antrone Antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine Antineoplastics (arabinofuranosyl derivatives) fazarabine; fludarabine aril-, -aril, -aril- Antiviral (arildone derivatives) pleconaril; arildone; fosarilate -arit Antirheumatics (lobenzarit type) lobenzarit; clobuzarit -arol
    [Show full text]
  • Ep 1270000 A2
    Europäisches Patentamt *EP001270000A2* (19) European Patent Office Office européen des brevets (11) EP 1 270 000 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 31/00, A61K 31/353, 02.01.2003 Bulletin 2003/01 A61P 9/10 (21) Application number: 02254274.0 (22) Date of filing: 19.06.2002 (84) Designated Contracting States: • Bourassa, P.-A., AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Pfizer Global Research and Devel. MC NL PT SE TR Groton, Connecticut 06340 (US) Designated Extension States: • Lindsey, S., AL LT LV MK RO SI Pfizer Global Research and Developm. Groton, Connecticut 06340 (US) (30) Priority: 28.06.2001 US 301712 P 10.10.2001 US 328254 P (74) Representative: Sewell, Richard Charles et al UK Patent Department, (71) Applicant: Pfizer Products Inc. Pfizer Limited, Groton, Connecticut 06340 (US) Ramsgate Road Sandwich, Kent CT13 9NJ (GB) (72) Inventors: • Aiello, R. J., Pfizer Global Research and Develop. Groton, Connecticut 06340 (US) (54) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis (57) A method of treating atherosclerosis in a mammal, including a human, comprising administering to said mam- mal an amount of the compound of the formula an enantiomer, or the pharmaceutically acceptable salt thereof; effective to treat atherosclerosis, wherein R1, R2 and R3 are as defined herein. EP 1 270 000 A2 Printed by Jouve, 75001 PARIS (FR) EP 1 270 000 A2 Description BACKGROUND OF THE INVENTION 5 [0001] This invention relates to the methods of treating atherosclerosis in a mammal, including a human, by admin- istering an amount of LTB4 antagonists, preferably substituted benzopyrans or a pharmaceutically acceptable salt thereof, effective in treating atherosclerosis.
    [Show full text]